Compare Elder Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA NOVARTIS ELDER PHARMA/
NOVARTIS
 
P/E (TTM) x -0.2 472.1 - View Chart
P/BV x 0.1 27.4 0.4% View Chart
Dividend Yield % 0.0 1.7 -  

Financials

 ELDER PHARMA   NOVARTIS
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
NOVARTIS
Mar-18
ELDER PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs380758 50.1%   
Low Rs188579 32.5%   
Sales per share (Unadj.) Rs491.2228.4 215.1%  
Earnings per share (Unadj.) Rs-3.231.7 -10.0%  
Cash flow per share (Unadj.) Rs14.432.8 44.0%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs376.5297.1 126.7%  
Shares outstanding (eoy) m20.5424.69 83.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.62.9 19.8%   
Avg P/E ratio x-89.321.1 -423.8%  
P/CF ratio (eoy) x19.720.4 96.6%  
Price / Book Value ratio x0.82.2 33.5%  
Dividend payout %031.5 0.0%   
Avg Mkt Cap Rs m5,83316,505 35.3%   
No. of employees `000NA0.7 0.0%   
Total wages/salary Rs m2,1791,445 150.8%   
Avg. sales/employee Rs ThNM8,441.3-  
Avg. wages/employee Rs ThNM2,163.6-  
Avg. net profit/employee Rs ThNM1,173.1-  
INCOME DATA
Net Sales Rs m10,0895,639 178.9%  
Other income Rs m2571,718 14.9%   
Total revenues Rs m10,3467,357 140.6%   
Gross profit Rs m-792-63 1,267.0%  
Depreciation Rs m36125 1,428.1%   
Interest Rs m2,75655 4,984.3%   
Profit before tax Rs m-3,6531,575 -231.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125792 15.8%   
Profit after tax Rs m-65784 -8.3%  
Gross profit margin %-7.8-1.1 708.2%  
Effective tax rate %-3.450.3 -6.8%   
Net profit margin %-0.613.9 -4.7%  
BALANCE SHEET DATA
Current assets Rs m9,2409,522 97.0%   
Current liabilities Rs m9,9983,296 303.3%   
Net working cap to sales %-7.5110.4 -6.8%  
Current ratio x0.92.9 32.0%  
Inventory Days Days4637 126.5%  
Debtors Days Days6028 210.9%  
Net fixed assets Rs m10,12446 22,008.0%   
Share capital Rs m206123 166.7%   
"Free" reserves Rs m5,5827,213 77.4%   
Net worth Rs m7,7347,336 105.4%   
Long term debt Rs m4,8890-   
Total assets Rs m22,88211,105 206.0%  
Interest coverage x-0.329.5 -1.1%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.5 86.8%   
Return on assets %11.87.6 155.7%  
Return on equity %-0.810.7 -7.9%  
Return on capital %22.322.2 100.4%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30761 505.9%   
Fx outflow Rs m1253,630 3.5%   
Net fx Rs m181-3,570 -5.1%   
CASH FLOW
From Operations Rs m11,7541,610 730.1%  
From Investments Rs m-561687 -81.6%  
From Financial Activity Rs m-6,762-2,677 252.6%  
Net Cashflow Rs m4,432-380 -1,167.5%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.5 2.0 375.0%  
FIIs % 16.8 1.6 1,050.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 21.5 167.9%  
Shareholders   16,479 41,647 39.6%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   ORCHID PHARMA LTD  CIPLA  GLENMARK PHARMA  JUBILANT LIFE SCIENCES  STRIDES PHARMA SCIENCE  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 292 Points Higher; Automobile and Metal Stocks Witness Buying(Closing)

After opening the day marginally higher, Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS